Curated News
By: NewsRamp Editorial Staff
August 12, 2025
Branded Legacy Acquires Bio Legacy to Combat Global Health Challenges
TLDR
- Branded Legacy's acquisition of Bio Legacy Evaluative Group for $1.5 million in Preferred D shares positions it to capitalize on the growing $1.16 billion intranasal naloxone market by 2032.
- The all-stock deal includes performance-based conversion milestones, a two-year lock-up, and a $1 million R&D commitment post-uplisting to OTCQB, enhancing Branded Legacy's biotech portfolio.
- This acquisition enables Branded Legacy to tackle global health issues like the addiction epidemic and vaccine distribution inefficiencies, improving public health outcomes worldwide.
- Branded Legacy now owns a patented intranasal naloxone device and nasal delivery technology for vaccines, marking a significant leap in health and wellness innovation.
Impact - Why it Matters
This acquisition is a game-changer in the health and wellness industry, particularly in addressing the global addiction epidemic and improving vaccine distribution. With the introduction of an innovative intranasal naloxone device and nasal vaccine delivery technology, Branded Legacy is poised to make significant strides in public health, offering new solutions to save lives and enhance healthcare delivery worldwide.
Summary
Branded Legacy (OTC: BLEG), a leader in the health and wellness sector, has successfully acquired Bio Legacy Evaluative Group, previously known as Menlo Health, in a significant all-stock transaction valued at $1.5 million. This strategic move, finalized on July 31, 2025, is set to bolster Branded Legacy's capabilities in tackling pressing global health issues, including the addiction crisis and challenges in vaccine distribution. Spearheaded by CEO Amin Janmohamed, Bio Legacy introduces a groundbreaking all-in-one intranasal naloxone device, tapping into a market expected to surge from $371 million in 2022 to over $1.16 billion by 2032. Additionally, the company brings to the table innovative technology for the nasal delivery of vaccines and therapies requiring cold-chain logistics. The deal encompasses performance-based conversion milestones, a two-year lock-up period, and a $1 million R&D pledge following the company's uplisting to OTCQB.
For further details, the full press release is available at https://ibn.fm/U7eSy. Branded Legacy continues to pioneer in the biotech and wellness industry, committed to innovation, strategic expansion, and delivering sustainable value to its stakeholders. More information can be found on their website at https://BrandedLegacy.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Branded Legacy Acquires Bio Legacy to Combat Global Health Challenges
